News and Disclosures
- News
- Disclosures
-
Ibnsina Pharma Issues First Sustainability Report 05 June 2023
-
Ibnsina Pharma Releases Audited 1H21 Results 16 August 2021
-
Ibnsina Pharma Releases Audited 1Q21 Results 31 May 2021
-
Ibnsina Pharma Releases Audited FY20 Results 01 March 2021
-
Ibnsina Pharma Releases Audited 9M20 Results 15 November 2020
-
Ibnsina Pharma Releases Audited 1H20 Results 13 August 2020
-
Ibnsina Pharma Releases Audited 1Q20 Results 09 June 2020
-
Ibnsina Pharma Releases Audited FY19 Results 24 February 2020
-
Ibnsina Pharma Releases Audited 9M19 Results 04 November 2019
-
Ibnsina Pharma Releases Audited 1H19 Results 06 August 2019
-
Ibnsina Pharma Releases Audited 1Q19 Results 12 May 2019
-
Ibnsina Pharma Releases Audited FY2018 Results 07 March 2019
-
Ibnsina Pharma Starts Distributing Alcon Products in Egypt 13 January 2019
-
Ibnsina Pharma Releases Audited 9M18 Results 11 November 2018
-
Release from Ibnsina Pharma Concerning the CEO 01 October 2018
-
Ibnsina Pharma Releases Audited 1H18 Results 13 August 2018
-
Ibnsina Pharma Releases Audited 1Q2018 Results 14 May 2018
-
Ibnsina Pharma Releases Audited FY2017 Results 11 March 2018
-
Ibnsina Pharma Releases Unaudited FY2017 Results 04 March 2018
-
Price Range Announcement 22 November 2017
-
Ibnsina Pharma Announces a Stock Split of 1:4 (Arabic Only) 11 October 2017
-
Ibnsina Pharma (ISPH.CA) - Disclosure Form for the BoD & the Shareholders' Structure 14 January 2019
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/12/2018 according to Article 30 of the Listing Rules.
225432-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) 13 January 2019
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company stating that it will begin distributing the products of the company "Alcon" during the first quarter of 2019.
225324-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning a Lawsuit 20 December 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company stating that the lawsuit was adjourned to be on 19/02/2019
224781-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning a Lawsuit 21 November 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company stating that the lawsuit no. 1898 for the year 2016 was adjourned to be on 19/12/2018.
223941-1.pdf
-
Ibnsina Pharma (ISPH.CA)- Board of Directors' Decisions 11 November 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : The Board of Directors' decisions held on 08/11/2018
-
Release from Ibnsina Pharma (ISPH.CA) Regarding the Financial Results 11 November 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company regarding the financial results for the period ended 30/09/2018
-
Ibnsina Pharma (ISPH.CA) Reports 9 Months Results 11 November 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/09/2018
Net Profit : 188,349,963
F/S Period: From 01/01/2017 To 30/09/2017
Net Comparative Profit : 143,079,626
Audit Status : Reviewed
Source : Ibnsina Pharma
-
Ibnsina Pharma (ISPH.CA) Reports 9 Months Results 11 November 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/09/2018
Net Profit : 188,349,963
F/S Period: From 01/01/2017 To 30/09/2017
Net Comparative Profit : 143,079,626
Audit Status : Reviewed
Source : Ibnsina Pharma
-
Release from Ibnsina Pharma (ISPH.CA) Regarding the BOD's Meeting 05 November 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company regarding the BOD's meeting to be held on 08/11/2018
223081-1.pdf
-
Ibnsina Pharma (ISPH.CA) - AGM Minutes (after Certification) 30 October 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
AGM minutes (after certification)
Assembly Date : 02/04/2018
222923-1.pdf
-
Ibnsina Pharma (ISPH.CA) Disclosure Form concerning the BoD & the Shareholders' Structure 15 October 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 30/09/2018, according to Article 30 of the Listing Rules.
222414-1.pdf
-
Resume of Trading on Ibnsina Pharma (ISPH.CA) 01 October 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
EGX decided to resume trading on the company effective 01/10/2018 trading session at 2:20 PM.
-
Release from Ibnsina Pharma (ISPH.CA) Responding to EGX Inquiries 01 October 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent a release regarding the news published on one of the websites titled "The arrest of the Managing Director of Ibn Sina Pharma due to the issue of drug monopoly".
221763-1.pdf
-
Suspension of Trading on Ibnsina Pharma (ISPH.CA) 01 October 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
EGX decided to suspend trading on the company effective 01/10/2018 till the company responds to EGX inquiries concerning what was published on one of the websites. -
Release from Ibnsina Pharma (ISPH.CA) Concerning A Lawsuit 19 September 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company stating that the lawsuit was adjourned to be on 19/11/2018
221236-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning the Semi-annual Disclosure Form 12 September 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release concerning the semi-annual disclosure form concerning the proceeds of the capital increase.
220976-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Board of Directors' Decisions 12 August 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' decisions held on 09/08/2018.
Release in Arabic (1,745 KB)
219979-2.pdf
219979-3.pdf
-
Ibnsina Pharma (ISPH.CA) Reports 6 Months Results 12 August 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/06/2018
Net Profit : 75,183,179
F/S Period: From 01/01/2017 To 30/06/2017
Net Comparative Profit : 53,662,578
Audit Status : Reviewed
Source : Ibnsina Pharma
219980-1.pdf
-
Ibnsina Pharma (ISPH.CA) Reports 6 Months Results 12 August 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/06/2018
Net Profit : 75,183,179
F/S Period: From 01/01/2017 To 30/06/2017
Net Comparative Profit : 53,662,578
Audit Status : Reviewed
Source : Ibnsina Pharma
219980-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Regarding the BOD's Meeting 31 July 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent regarding the BOD's meeting to be held on 09/08/2018
219547-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning a Lawsuit 17 July 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Reference to what was published on 20/06/2018, the company sent a release from stating that the lawsuit was adjourned to 18/09/2018.
219202-1.pdf
-
Ibnsina Pharma (ISPH.CA) Disclosure Form for the BoD & the Shareholders' Structure 11 July 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 30/06/2018 according to Article 30 of the Listing Rules.
218944-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) 05 July 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company denying the existence of any contractual relations or association with Abraaj Capital Group
218662-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning A Lawsuit 20 June 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company stating that the lawsuit was adjourned to 16/07/2018
218149-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Listing Committee Decision 07 June 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Listing Committee held on 06/06/2018 decided to address the company to abide by the provision of Article 31 of the Listing Rules and 45 of the Executive Regulations.
-
Release from Ibnsina Pharma (ISPH.CA) Regarding A Lawsuit 20 May 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent regarding a lawsuit against the company, with a session scheduled for Monday 19/06/2018
217180-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning the Financial Results 15 May 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent concerning the financial results for the period ended 31/03/2018
216841-2.pdf
216841-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Board Of Directors' Decisions 14 May 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : The Board of Directors' decisions held on 13/05/2018
216748-1.pdf
-
Ibnsina Pharma (ISPH.CA) Reports 3 Months Results 14 May 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 31/03/2018
Net Profit : 27,954,173
F/S Period: From 01/01/2017 To 31/03/2017
Net Comparative Profit : 19,105,202
Audit Status : Reviewed
Source : Ibnsina Pharma
216749.pdf
-
Ibnsina Pharma (ISPH.CA) Reports 3 Months Results 14 May 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 31/03/2018
Net Profit : 27,954,173
F/S Period: From 01/01/2017 To 31/03/2017
Net Comparative Profit : 19,105,202
Audit Status : Reviewed
Source : Ibnsina Pharma
216749-1.pdf
-
Release From Ibnsina Pharma (ISPH.CA) Regarding the BOD's Meeting 10 May 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company regarding the BOD's meeting to be held on 13/05/2018
216513-1.pdf
-
Ibnsina Pharma, Listing shares of the company's capital increase. 18 April 2018
ISPH.CA
The listing committee held on 17-04-2018 has approved to list the company's capital increase from EGP 168 Million to EGP 180.5 Million , such capital increase amounted to EGP 12.5 Million distributed over 50 Million shares at par value of EGP 0.25 per share paid in cash .
These new shares will be added to Egx database starting 24/04/2018 trading session.
The company is committed to lock-up all shares of this capital increase that amounted to 50,000,000 shares to fulfill terms of its share lock-up as set in the placement prospectus of the company's shares , in accordance with the item no. (7) of the article no. (7) of the listing rules, provided that the lock-up period shall be completed for "eighteen months from the date of trading its shares in the Egyptian Exchange" according to the letter received from MCDR on 16\04\2018.
-
Ibnsina Pharma (ISPH.CA) - Disclosure Form for the BoD & the Shareholders' Structure 16 April 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/03/2018 according to Article 30 of the Listing Rules.
215552-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning the BOD & Executive Managers 05 April 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company concerning the Board of Directors & the Executive Managers.
215102-1.pdf
-
Ibnsina Pharma (ISPH.CA) - AGM Decisions 03 April 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
AGM Decisions
Assembly Date : 02/04/2018
214910-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Audit Committee’s Minutes 27 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :The Audit Committee’s minutes for the period ended 31/12/2017
214456-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) 26 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company concerning the completion of the commercial register and the release of the proceeds of the capital increase of 290 million pounds
214204-1.pdf
-
Release Ibnsina Pharma (ISPH.CA) Concerning the Signing of Two Contracts 20 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Press release regarding the signing of two contracts with Novo Nordisk Company.
214204-2.pdf
214204-1.pdf
-
Ibnsina Pharma (ISPH.CA) Reports Year Ended 12/31/2017 Results 11 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2017 To 31/12/2017
Net Profit : 170,137,041
F/S Period: From 01/01/2016 To 31/12/2016
Net Comparative Profit : 101,747,851
Audit Status : Audited
Source : Ibnsina Pharma
213851-2.pdf
213851-3.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning the Call for the AGM 11 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company concerning the call for the AGM which is scheduled to be held on 02/04/2018
213854-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Board of Directors' Decisions 11 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :The Board of Directors' decisions held on08/03/2018
213853-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Board of Directors' Meeting 05 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' meeting minutes held on 04/03/2018 concerning the unaudited financial results for the period ended 31/12/2017. The Minutes (2,686 KB)
213488-3.pdf
213488-2.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concenring a Lawsuit 04 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Referring to the announcement published on the trading screens regarding the latest developments of case no. 2952 for the year 2015, the economic census and number 1898 for the year 2016 economic misdemeanors and clarification from the company note that the company appealed the ruling before the competent authorities and was set on Saturday, 19/05/2018 in front of Second Circuit Resume.
213413-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Concerning a Lawsuit 01 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company concerning the latest developments of the case No. 2952 for the year 2015 inventory commercial restricted number 1898 to 2016 commercial misdemeanors.
213346-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Board of Directors' Meeting Minutes 01 March 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' meeting minutes held on 28/02/2018.
213323-1.pdf
-
Release from Ibnsina Pharma (ISPH.CA) Regarding Its Sales 21 January 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company regarding its sales and market share.
211994-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Board of Directors' Meeting Minutes 18 January 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' meeting minutes held on 17/01/2018.
211938-1.pdf
-
Ibnsina Pharma (ISPH.CA) - EGM Minutes (after Certification) 18 January 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
EGM minutes (after certification)
Assembly Date : 01/11/2017
211944-1.pdf
-
Ibnsina Pharma (ISPH.CA) - Disclosure Form For The BoD & The Shareholders' Structure 15 January 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/12/2017 according to Article 30 of the Listing Rules.
211802-1.pdf
-
Release From Ibnsina Pharma (ISPH.CA) Regarding The Company's Stabilization Fund 04 January 2018
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent regarding the company's stabilization fund.
211438-1.pdf
-
Release From Ibnsina Pharma (IBNP.CA) Concerning The Investor Relations Officer 28 December 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :Release was sent concerning the investor relations officer
211307-1.pdf
-
Release From Ibnsina Pharma (IBNP.CA) Concerning The Board Of Directors & The Executive Managers 28 December 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content : Release was sent concerning the Board of Directors & the Executive Managers
211309-1.pdf
-
Ibnsina Pharma (IBNP.CA) EGM Minutes (After Certification) 19 December 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content : EGM minutes (after certification)
Assembly Date : 24/10/2017
211060-1.pdf
-
Ibnsina Pharma (IBNP.CA) - Disclosures From The Company 11 December 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Disclosures from the company. News' Attachment I (604 KB)
210775-2.pdf
210775-3.pdf
-
Ibnsina Pharma (IBNP.CA) - Disclosures From The Company 11 December 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Disclosures from the company. News' Attachment I (574 KB)
News' Attachment II (560 KB) News' Attachment III (626 KB)
210774-4.pdf
210774-5.pdf
-
Release From Ibnsina Pharma (IBNP.CA) 05 December 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Release regarding the final price of the company's share.
210673-1.pdf
-
Additional Release From Ibnsina Pharma (IBNP.CA) 27 November 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Additional release from the company.
210412-1.pdf
-
Ibnsina Pharma (IBNP.CA) - Disclosures From The Company 26 November 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Disclosures from the company. News' Attachment I (626 KB)
News' Attachment II (1,236 KB) News' Attachment III (3,232 KB)
210403-4.pdf
210403-5.pdf
-
Release Concerning Ibnsina Pharma (IBNP.CA) 23 November 2017
Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Release regarding FRA's approval on the prospectus of the initial public offering of the company.
News-Attachment-I.pdf
News-Attachment-II.pdf
-
Listing The Shares Of Ibnsina Pharma (IBNP.CA) 08 November 2017
The Listing Committee held on 08/11/2017 has approved to list the shares of Ibnsina Pharma (initially listing)
The company’s issued capital is EGP 168 Million, distributed over 672 million shares at a par value of LE 0.25 per share, to be listed in the Egyptian Securities Board- Stocks.
According to the Listing Rules set by EFSA board of directors’ resolution
